JLE

Hépato-Gastro & Oncologie Digestive

MENU

Iron deficiency in digestive oncology Volume 26, supplement 1, Octobre 2019

  • [1] Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer 2014 ; 22 (8) : 2197-206.
  • [2] Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-1602. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators10053
  • [3] Kassebaum N.J., Jasrasaria R., Naghavi M. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615-624. 5
  • [4] Ludwig H., Van Belle S., Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-2306. 15
  • [5] Ludwig H., Müldür E., Endler G., Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24:1886-1892. 7
  • [6] Saint A, Viotti J, Borchiellini D, et al. Iron deficiency during first-line chemotherapy in metastatic cancers : a prospective epidemiological study. Support Care Cancer. 2019 Jul 6 ; [Epub ahead of print].
  • [7] Beale A.L., Penney M.D., Allison M.C. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis. 2005;7:398-402. 4
  • [8] Tang G.H., Hart R., Sholzberg M., Brezden-Masley C. Iron deficiency anemia in gastric cancer: A Canadian retrospective review. Eur J Gastroenterol Hepatol. 2018;30:1497-1501. 12
  • [9] Steinbicker A.U., Muckenthaler M.U. Out of balance--systemic iron homeostasis in iron-related disorders. Nutrients. 2013;5:3034-3061. 8
  • [10] Hurrell R., Egli I. Iron bioavailability and dietary reference values. Am J Clin Nutr. 2010;91:1461S-1467S. 5
  • [11] Itkonen O., Stenman U.-H., Parkkinen J., Soliymani R., Baumann M., Hämäläinen E. Binding of hepcidin to plasma proteins. Clin Chem. 2012;58:1158-1160. 7
  • [12] Peeling P., Sim M., Badenhorst C.E. Iron status and the acute post-exercise hepcidin response in athletes. PloS One. 2014;9:e93002. 3
  • [13] Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678-684. 7
  • [14] Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol Baltim Md 1950 ; 2002 ; 169(4) : 2204-9.
  • [15] Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29(Suppl. 4) : iv96-110.
  • [16] Mast A.E., Blinder M.A., Gronowski A.M., Chumley C., Scott M.G. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44:45-51. 1
  • [17] Infusino I., Braga F., Dolci A., Panteghini M. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. Am J Clin Pathol. 2012;138:642-649. 5
  • [18] Malope B.I., MacPhail A.P., Alberts M., Hiss D.C. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol. 2001;115:84-89. 1
  • [19] Das S., Philip K.J. Evaluation of iron status: Zinc protoporphyrin vis-a-vis bone marrow iron stores. Indian J Pathol Microbiol. 2008;51:105-107. 1
  • [20] Tessitore N., Solero G.P., Lippi G. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:1416-1423. 7
  • [21] Brugnara C., Schiller B., Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28:303-308. 5
  • [22] Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001 ; 91 (12) : 2214-21.
  • [23] Pedrazzoli P., Farris A., Del Prete S. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008;26:1619-1625. 10
  • [24] Auerbach M., Ballard H., Trout J.R. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol. 2004;22:1301-1307. 7
  • [25] Bastit L., Vandebroek A., Altintas S. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26:1611-1618. 10
  • [26] Hedenus M., Birgegård G., Näsman P. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia. 2007;21:627-632. 4
  • [27] Gafter-Gvili A., Rozen-Zvi B., Vidal L. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol Stockh Swed. 2013;52:18-29. 1
  • [28] Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012 ; 138 (2) : 179-87.
  • [29] Kim Y.T., Kim S.W., Yoon B.S. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105:199-204. 1
  • [30] Toledano A, Luporsi E, Morere JF, et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 2016 ; 24 (1) : 67-75.
  • [31] Anker S.D., Comin Colet J., Filippatos G. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-2448. 25
  • [32] Comin-Colet J., Lainscak M., Dickstein K. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study. Eur Heart J. 2013;34:30-38. 1
  • [33] Ponikowski P., van Veldhuisen D.J., Comin-Colet J. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668. 11
  • [34] Ludwig H., Evstatiev R., Kornek G. Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr. 2015;127:907-919. 23-24
  • [35] Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet 2016 ; 387 (10021) : 907-16.
  • [36] Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013 ; 24 (2) : 475-82.
  • [37] Michael B., Coyne D.W., Fishbane S. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-1839. 5
  • [38] Auerbach M., Silberstein P.T., Webb R.T. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010;85:655-663. 9